Alzheimer’s Disease – The Past, the Present and the Future
Benson Opare Asamoah Botchway,
Ishwari Chandran Iyer
Issue:
Volume 6, Issue 1, January 2017
Pages:
1-19
Received:
20 December 2016
Accepted:
7 January 2017
Published:
3 February 2017
Abstract: Alzheimer’s disease (hereafter: AD) is an irreversible, slowly progressive disease of the brain, most often categorized under the umbrella term ‘neurodegeneration’. It is said to be a progressive disease in a sense that the symptoms associated with AD, the most common one being difficulty in remembering recent events, kick in steadily with the symptoms getting worse as time goes on, leading to the demise of affected person as they eventually lose their bodily functions. Other symptoms associated with AD include language problems, mood swings and disorientation. This report seeks to address the history, current as well as the future state of AD by taking into consideration the probable causes and preventive mechanisms together with the treatment methods.
Abstract: Alzheimer’s disease (hereafter: AD) is an irreversible, slowly progressive disease of the brain, most often categorized under the umbrella term ‘neurodegeneration’. It is said to be a progressive disease in a sense that the symptoms associated with AD, the most common one being difficulty in remembering recent events, kick in steadily with the symp...
Show More
Effects of Ticlopidine on Platelet Aggregation in Beagles with Unstable Angina
Weiting Wang,
Chunhua Hao,
Zhuanyou Zhao
Issue:
Volume 6, Issue 1, January 2017
Pages:
20-23
Received:
12 February 2017
Accepted:
4 March 2017
Published:
21 March 2017
Abstract: Aim To study the antiplatelet aggregation of ticlopidine (TC). Methods Using coronary artery Folts, model in beagles, the efficacy of TC on platelet aggregation was studied. Results (1)TC16, 32 mg•kg-1 dramatically inhibited the frequency of CFRs dose-dependently, and the times of CFRs decreased by 27%, 56%, 95%, 100% respectively at 1-4 h than that in control group’s after TC 32 mg•kg-1 administration. CFRs were abolished and did not return when AD was infused after TC 32 mg•kg-1 administration. (2)The time for CFRs absolute disappearance of TC in dose of 32 mg•kg-1 was shorter than that in control group. (3)The platelet aggregation induced by ADP was inhibited obviously after TC 16,32 mg•kg-1 administration, and the aggregation in TC 32 mg•kg-1 didn’t return after AD administration. Conclusion TC had dose-dependent antiplatelet effects in beagles, suggesting TC has reliable therapeutical efficacy on angina pectoris.
Abstract: Aim To study the antiplatelet aggregation of ticlopidine (TC). Methods Using coronary artery Folts, model in beagles, the efficacy of TC on platelet aggregation was studied. Results (1)TC16, 32 mg•kg-1 dramatically inhibited the frequency of CFRs dose-dependently, and the times of CFRs decreased by 27%, 56%, 95%, 100% respectively at 1-4 h than tha...
Show More
